Based on the corresponding carcinogenic mechanisms, we selected the significant biomarkers NFKB1, LEF1 and MYC as drug targets for MIBC, and the significant biomarkers LEF1, MYC, NOTCH1 and FOXO1 as drug targets for ABC. This evidence concerns the gene MYC and aneurysmal bone cyst.